Apellis Pharmaceuticals, Inc. (APLS) Misses Q1 EPS by 40c
Tweet
Share
E-mailGet Alerts APLS Hot Sheet
Join SI Premium – FREE
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q1 EPS of ($0.74), $0.40 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $166.8 million versus the consensus estimate of $197.77 million.
For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
